CDNA · Insider Trading
CareDx, Inc.
Every open-market purchase and sale reported by CDNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Jessica Meng | Chief Commercial Officer | F | −2,619 | −$173.46K |
| 2026-10-05 | Keith Kennedy | CFO & COO | F | −3,018 | −$199.88K |
| 2026-10-05 | Jeffrey Adam Novack | Secretary and General Counsel | F | −997 | −$66.03K |
| 2026-10-05 | John Walter Hanna JR | President and CEO | F | −8,511 | −$563.68K |
| 2026-10-05 | Michael Goldberg | Director | A | +588 | — |
| 2026-09-15 | Jessica Meng | Chief Commercial Officer | F | −6,688 | −$350.25K |
| 2026-09-15 | Keith Kennedy | CFO & COO | F | −8,220 | −$430.48K |
| 2026-08-06 | George Bickerstaff | Director | Sell | −20,000 | −$925.70K |
| 2026-08-06 | Michael Goldberg | Director | Sell | −44,700 | −$2.10M |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | −2,688 | −$124.35K |
| 2026-08-06 | Christine Cournoyer | Director | Sell | −16,000 | −$750.97K |
| 2026-08-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | −2,688 | −$124.35K |
| 2026-08-06 | George Bickerstaff | Director | Sell | −20,000 | −$925.70K |
| 2026-08-06 | Michael Goldberg | Director | Sell | −44,700 | −$2.10M |
| 2026-08-06 | Christine Cournoyer | Director | Sell | −16,000 | −$750.97K |
| 2026-08-04 | Jeffrey Adam Novack | Secretary and General Counsel | F | −2,872 | −$137.43K |
| 2026-07-17 | John Walter Hanna JR | President and CEO | MIXED | — | −$3.49M |
| 2026-07-17 | Hannah Valantine | Director | MIXED | — | −$615.35K |
| 2026-07-07 | Michael Goldberg | Director | A | +1,746 | — |
| 2026-07-06 | John Walter Hanna JR | President and CEO | F | −8,511 | −$248.95K |
| 2026-07-02 | Jeffrey Adam Novack | Secretary and General Counsel | F | −997 | −$29.16K |
| 2026-07-02 | Keith Kennedy | CFO & COO | F | −2,930 | −$85.70K |
| 2026-07-02 | Jessica Meng | Chief Commercial Officer | F | −2,411 | −$70.52K |
| 2026-06-17 | John Walter Hanna JR | President and CEO | Sell | −17,683 | −$424.88K |
| 2026-06-16 | Michael Goldberg | Director | A | +9,795 | — |
| 2026-06-16 | Suresh Gunasekaran | Director | A | +9,795 | — |
| 2026-06-16 | Hannah Valantine | Director | MIXED | −2,308 | −$279.73K |
| 2026-06-16 | George Bickerstaff | Director | A | +9,795 | — |
| 2026-06-16 | Fred E Cohen | Director | A | +9,795 | — |
| 2026-06-16 | Richard Bryan Riggsbee | Director | A | +9,795 | — |
| 2026-06-16 | Christine Cournoyer | Director | A | +9,795 | — |
| 2026-06-15 | John Walter Hanna JR | President and CEO | Sell | −21,998 | −$528.44K |
| 2026-06-09 | Jeffrey Adam Novack | Secretary and General Counsel | F | −1,292 | −$28.36K |
| 2026-06-08 | John Walter Hanna JR | President and CEO | Sell | −4,835 | −$116.04K |
| 2026-05-18 | Arthur A Torres | Director | Sell | −10,570 | −$214.68K |
| 2026-05-06 | Jeffrey Adam Novack | Secretary and General Counsel | Sell | −2,688 | −$55.58K |
| 2026-05-04 | Jeffrey Adam Novack | Secretary and General Counsel | F | −2,873 | −$61.77K |
| 2026-04-22 | Keith Kennedy | CFO & COO | A | +24,134 | — |
| 2026-04-20 | John Walter Hanna JR | President and CEO | Sell | −10,282 | −$217.16K |
| 2026-04-16 | John Walter Hanna JR | President and CEO | F | −62,049 | −$1.09M |
| 2026-04-07 | Jeffrey Adam Novack | Secretary and General Counsel | F | −1,892 | −$33.72K |
| 2026-04-03 | Jeffrey Adam Novack | Secretary and General Counsel | F | −3,987 | −$71.25K |
| 2026-04-03 | Michael Goldberg | Director | A | +1,981 | — |
| 2026-04-03 | Jessica Meng | Chief Commercial Officer | F | −7,386 | −$131.99K |
| 2026-04-03 | Keith Kennedy | CFO & COO | F | −11,725 | −$209.53K |
| 2026-04-03 | John Walter Hanna JR | President and CEO | F | −35,037 | −$626.11K |
| 2026-04-01 | Michael Goldberg | Director | M | +26,500 | +$88.65K |
| 2026-02-04 | John Walter Hanna JR | President and CEO | MIXED | +186,438 | −$279.63K |
| 2026-02-04 | Jeffrey Adam Novack | Secretary and General Counsel | MIXED | +27,439 | −$202.82K |
| 2026-02-04 | Keith Kennedy | Chief Operating Officer | MIXED | +69,830 | −$94.83K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| John Walter Hanna JR | President and CEO | 644,937 | $44.57M |
| Abhishek Jain | Chief Financial Officer | 319,725 | $22.09M |
| Peter Maag | Director | 309,846 | $21.41M |
| Keith Kennedy | CFO & COO | 208,686 | $14.42M |
| Fred E Cohen | Director | 165,060 | $11.41M |
| Jessica Meng | Chief Commercial Officer | 158,980 | $10.99M |
| Michael Goldberg | Director | 153,371 | $10.60M |
| George Bickerstaff | Director | 134,061 | $9.26M |
| Jeffrey Adam Novack | Secretary and General Counsel | 105,078 | $7.26M |
| Nathan Smith | Chief Financial Officer | 75,000 | $5.18M |
| William A Hagstrom | Director | 73,370 | $5.07M |
| Hannah Valantine | Director | 44,292 | $3.06M |
| Christine Cournoyer | Director | 42,943 | $2.97M |
| Richard Bryan Riggsbee | Director | 39,312 | $2.72M |
| Arthur A Torres | Director | 38,665 | $2.67M |
| Suresh Gunasekaran | Director | 37,248 | $2.57M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CDNA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.